CDKN2A and neoplasm: This finding suggested that the P16 gene may have previously unknown tumor suppressive potential and may play a role in mitigating the biological outcomes of P16 inactivation by disrupting the negative feedback loop (i.e., inhibiting UTPA14 expression and K810 ubiquitination of RB1).